A European study of views on the use of monoamine oxidase inhibitors.
A total of 1269 psychiatrists, from 15 European countries, completed a questionnaire assessing treatment choice in depressive and anxiety disorders, with particular focus on diagnostic and other factors determining use of monoamine oxidase inhibitors (MAOIs). Tricyclic and similar antidepressants were used most commonly--MAOIs were used as first-choice therapy for depressive or anxiety disorders only by a minority but were commonly a second-choice treatment for atypical depressives. Use was inhibited by interactions and side-effects rather than by perceived ineffectiveness. Cross-national differences in treatment were considerable but diagnostic differences in case history vignettes were much smaller.
Paykel
E S
ES
University of Cambridge, Addenbrooke's Hospital, UK.
White
J L
JL
D000275:Adjustment Disorders / Q000188:drug therapy; D001008:Anxiety Disorders / Q000188:drug therapy; D001291:Attitude of Health Personnel; D003431:Cross-Cultural Comparison; D003866:Depressive Disorder / Q000188:drug therapy*; D005060:Europe; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
D008996:Monoamine Oxidase Inhibitors